The drug Evusheld combines two long-acting antibodies — tixagevimab and cilgavimab — that aid the immune system in fending off the coronavirus.
Early laboratory findings have shown that the drug was effective against variants of concern, including the predominant Delta strain of the coronavirus, said the firm. The drug is being studied in a comprehensive clinical trial programme for the treatment and prevention of Covid-19 in more than 9,000 participants.
Mr Vinod Narayanan, country president of AstraZeneca Singapore, said that the drug would provide another prevention option for people at high risk of contracting Covid-19, alongside vaccines. These include persons who have weakened immune systems and cannot develop the necessary degree of protective response after vaccination.
Is it approved by HSA, or are we giving it away to Johor again.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.